Arbutus Biopharma Corp Stock Market Value
| ABUS Stock | USD 4.16 0.11 2.72% |
| Symbol | Arbutus |
Is there potential for Biotechnology market expansion? Will Arbutus introduce new products? Factors like these will boost the valuation of Arbutus Biopharma. If investors know Arbutus will grow in the future, the company's valuation will be higher. Understanding fair value requires weighing current performance against future potential. All the valuation information about Arbutus Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.23) | Revenue Per Share | Quarterly Revenue Growth (0.60) | Return On Assets | Return On Equity |
Arbutus Biopharma Corp's market price often diverges from its book value, the accounting figure shown on Arbutus's balance sheet. Smart investors calculate Arbutus Biopharma's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Since Arbutus Biopharma's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Understanding that Arbutus Biopharma's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Arbutus Biopharma represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. However, Arbutus Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Arbutus Biopharma 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Arbutus Biopharma's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Arbutus Biopharma.
| 11/14/2025 |
| 02/12/2026 |
If you would invest 0.00 in Arbutus Biopharma on November 14, 2025 and sell it all today you would earn a total of 0.00 from holding Arbutus Biopharma Corp or generate 0.0% return on investment in Arbutus Biopharma over 90 days. Arbutus Biopharma is related to or competes with ARS Pharmaceuticals, Nanobiotix, GH Research, Tango Therapeutics, Bicara Therapeutics, Septerna Common, and Eyepoint Pharmaceuticals. Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus in... More
Arbutus Biopharma Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Arbutus Biopharma's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Arbutus Biopharma Corp upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.04) | |||
| Maximum Drawdown | 20.16 | |||
| Value At Risk | (5.79) | |||
| Potential Upside | 5.47 |
Arbutus Biopharma Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Arbutus Biopharma's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Arbutus Biopharma's standard deviation. In reality, there are many statistical measures that can use Arbutus Biopharma historical prices to predict the future Arbutus Biopharma's volatility.| Risk Adjusted Performance | (0.0002) | |||
| Jensen Alpha | (0.16) | |||
| Total Risk Alpha | (0.46) | |||
| Treynor Ratio | (0.04) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Arbutus Biopharma's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Arbutus Biopharma February 12, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.0002) | |||
| Market Risk Adjusted Performance | (0.03) | |||
| Mean Deviation | 2.58 | |||
| Coefficient Of Variation | (9,985) | |||
| Standard Deviation | 3.54 | |||
| Variance | 12.54 | |||
| Information Ratio | (0.04) | |||
| Jensen Alpha | (0.16) | |||
| Total Risk Alpha | (0.46) | |||
| Treynor Ratio | (0.04) | |||
| Maximum Drawdown | 20.16 | |||
| Value At Risk | (5.79) | |||
| Potential Upside | 5.47 | |||
| Skewness | (0.84) | |||
| Kurtosis | 2.38 |
Arbutus Biopharma Corp Backtested Returns
Arbutus Biopharma Corp secures Sharpe Ratio (or Efficiency) of -0.0204, which signifies that the company had a -0.0204 % return per unit of standard deviation over the last 3 months. Arbutus Biopharma Corp exposes twenty-two different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Arbutus Biopharma's mean deviation of 2.58, and Risk Adjusted Performance of (0.0002) to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of 1.26, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Arbutus Biopharma will likely underperform. At this point, Arbutus Biopharma Corp has a negative expected return of -0.0734%. Please make sure to confirm Arbutus Biopharma's information ratio, as well as the relationship between the potential upside and rate of daily change , to decide if Arbutus Biopharma Corp performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.75 |
Almost perfect reverse predictability
Arbutus Biopharma Corp has almost perfect reverse predictability. Overlapping area represents the amount of predictability between Arbutus Biopharma time series from 14th of November 2025 to 29th of December 2025 and 29th of December 2025 to 12th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Arbutus Biopharma Corp price movement. The serial correlation of -0.75 indicates that around 75.0% of current Arbutus Biopharma price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.75 | |
| Spearman Rank Test | -0.62 | |
| Residual Average | 0.0 | |
| Price Variance | 0.12 |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Arbutus Stock Analysis
When running Arbutus Biopharma's price analysis, check to measure Arbutus Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arbutus Biopharma is operating at the current time. Most of Arbutus Biopharma's value examination focuses on studying past and present price action to predict the probability of Arbutus Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arbutus Biopharma's price. Additionally, you may evaluate how the addition of Arbutus Biopharma to your portfolios can decrease your overall portfolio volatility.